FDA approves label update of NovoLog

PRINCETON, N.J. Patients can store and use an insulin analog made by Novo Nordisk for more time, under changes to the drug’s labeling approved by the Food and Drug Administration.

The Danish drug maker announced Wednesday that the FDA had approved the labeling changes for NovoLog (insulin aspart [rDNA origin]), allowing patients to use the insulin in their pump for up to six days. The previous label allowed NovoLog to be stored in the pump reservoir for two days.

The pump is a battery-powered device about the size of a pager designed to pump insulin in to the patient’s body throughout the day according to a preset program, consisting of a reservoir, a small battery, a pump and a thin plastic tube with a needle on the end.